Literature DB >> 25561199

Epidemiology of actinic keratoses.

Adèle C Green1.   

Abstract

The epidemiology of actinic keratoses (AKs) reflects their causation by cumulative sun exposure, with the highest prevalence seen in pale-skinned people living at low latitudes and on the most sun-exposed body sites, namely the hands, forearms and face. AKs are markers of increased risk of basal cell carcinoma, squamous cell carcinoma and melanoma, especially when they are numerous and have coalesced into an area of 'field cancerisation'. The major risk factors are male sex, advanced age, sun-sensitive complexion, high lifetime sun exposure and prolonged immunosuppression. Clinical counts of AKs enable the assessment and monitoring of AK burden, but accurate counting is notoriously difficult, especially when skin is severely sun damaged. AK counting has been repeatedly shown to be unreliable, even among expert dermatologists. Notwithstanding these challenges, qualitative assessment of the natural history of AKs shows a high turnover, with new lesions developing and with other lesions regressing. A very small proportion of AKs undergo malignant transformation, but the precise rate of transformation is unknown due to the inaccuracies in monitoring AK lesions over time. Primary prevention of AKs is achieved by limiting intense sun exposure through sun-protective behaviour, including seeking deep shade, wearing sun-protective clothing and applying sunscreen regularly to exposed skin, from an early age.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25561199     DOI: 10.1159/000366525

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  8 in total

1.  Variation in the Cost of Managing Actinic Keratosis.

Authors:  Joslyn S Kirby; Tanner Gregory; Guodong Liu; Douglas L Leslie; Jeffrey J Miller
Journal:  JAMA Dermatol       Date:  2017-04-01       Impact factor: 10.282

Review 2.  Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.

Authors:  Nevena Skroza; Nicoletta Bernardini; Ilaria Proietti; Concetta Potenza
Journal:  Ther Clin Risk Manag       Date:  2018-10-04       Impact factor: 2.423

3.  Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic.

Authors:  Mahizer Yaldiz
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.

Authors:  Angeliki Befon; Vassiliki Tzanetakou; Antonios Panagiotopoulos; Vasiliki Chasapi; Christina Antoniou; Alexander J Stratigos
Journal:  Int J Dermatol       Date:  2019-02-19       Impact factor: 2.736

Review 5.  Topical Pharmacotherapy for Actinic Keratoses in Older Adults.

Authors:  Piergiacomo Calzavara-Pinton; Irene Calzavara-Pinton; Chiara Rovati; Mariateresa Rossi
Journal:  Drugs Aging       Date:  2022-02-14       Impact factor: 3.923

6.  Actinic Keratoses (AK): An Exploratory Questionnaire-Based Study of Patients' Illness Perceptions.

Authors:  Dimitrios Sgouros; Adamantia Milia-Argyti; Dimitrios K Arvanitis; Eleni Polychronaki; Fiori Kousta; Antonios Panagiotopoulos; Sofia Theotokoglou; Anna Syrmali; Konstantinos Theodoropoulos; Alexander Stratigos; Dimitrios Rigopoulos; Alexander Katoulis
Journal:  Curr Oncol       Date:  2022-07-21       Impact factor: 3.109

7.  Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel.

Authors:  Luigi Vimercati; Luigi De Maria; Antonio Caputi; Enza Sabrina Silvana Cannone; Francesca Mansi; Domenica Cavone; Paolo Romita; Giuseppe Argenziano; Alessandro Di Stefani; Aurora Parodi; Ketty Peris; Massimiliano Scalvenzi; Giampiero Girolomoni; Caterina Foti
Journal:  Int J Environ Res Public Health       Date:  2020-03-30       Impact factor: 3.390

Review 8.  Exposome and Skin. Part 2. The Influential Role of the Exposome, Beyond UVR, in Actinic Keratosis, Bowen's Disease and Squamous Cell Carcinoma: A Proposal.

Authors:  Manuel Molina-García; Josep Malvehy; Corinne Granger; Aurora Garre; Carles Trullàs; Susana Puig
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.